Literature DB >> 11711838

Effect of temperature and light on the stability of latanoprost and its clinical relevance.

P V Morgan1, S Proniuk, J Blanchard, R J Noecker.   

Abstract

PURPOSE: To examine the effect of controlled heat and ultraviolet exposures on the stability of latanoprost (Xalatan, Pharmacia & Upjohn, Kalamazoo, MI) using high-performance liquid chromatography to derive practical recommendations for patients regarding its use and storage.
METHODS: Using serial dilution of a latanoprost stock solution, varying concentrations were prepared to obtain a standard curve. The accuracy and precision of the high-performance liquid chromatography assay conditions were validated using between-day and within-day studies. The original latanoprost containers were stored at 4, 25, 50, and 70 degrees C, and the concentration of latanoprost remaining was measured by high-performance liquid chromatography at different times for up to 1 month. In addition, the original latanoprost containers were exposed to known amounts of ultraviolet A and B radiation for 4 hours, and the concentration of latanoprost was measured at 1-hour intervals using high-performance liquid chromatography.
RESULTS: The increased temperature studies showed that latanoprost remained stable at 4 and 25 degrees C for the 30-day study duration. Analysis of concentration versus time curves for 50 and 70 degrees C yielded a t90 (time for 10% degradation) of 8.25 and 1.32 days, respectively. Ultraviolet B radiation caused a rapid degradation of latanoprost, whereas ultraviolet A radiation was less effective in causing the degradation of latanoprost.
CONCLUSIONS: Latanoprost exhibits thermal and solar instability and should ideally be stored below room temperature and in the dark. The importance of these storage conditions should be conveyed clearly to the patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711838     DOI: 10.1097/00061198-200110000-00007

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

Review 1.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.

Authors:  Thomas V Johnson; Preeya K Gupta; Daljit K Vudathala; Ian A Blair; Angelo P Tanna
Journal:  J Ocul Pharmacol Ther       Date:  2010-11-30       Impact factor: 2.671

3.  [Original preparations versus generics--latanoprost: how similar is different?].

Authors:  M A Leitritz; H-P Lipp; B Voykov; F Ziemssen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

4.  In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.

Authors:  Joseph B Ciolino; Cristina F Stefanescu; Amy E Ross; Borja Salvador-Culla; Priscila Cortez; Eden M Ford; Kate A Wymbs; Sarah L Sprague; Daniel R Mascoop; Shireen S Rudina; Sunia A Trauger; Fabiano Cade; Daniel S Kohane
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

5.  Temperature instability of ReNu with MoistureLoc: a new theory to explain the worldwide Fusarium keratitis epidemic of 2004-2006.

Authors:  John D Bullock; Ronald E Warwar; B Laurel Elder; William I Northern
Journal:  Trans Am Ophthalmol Soc       Date:  2008

6.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

7.  Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study.

Authors:  Mauricio D Paolera; Niro Kasahara; Cristiano C Umbelino; John G Walt
Journal:  BMC Ophthalmol       Date:  2008-06-11       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.